Pharmaceutical intermediates
Paricalcitol Intermediates
6 pharmaceutical intermediates for Paricalcitol. Indication: Secondary hyperparathyroidism; Chronic renal insufficiency.
About Paricalcitol
- Originator
- Abbvie
- Indication
- Secondary hyperparathyroidism; Chronic renal insufficiency
- Approved Date
- 10/21/2014
Available intermediates
6 intermediates currently listed for Paricalcitol. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Paricalcitol | 131918-61-1 | / | / |
| (1R,3aR,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-diMethylhept-3-en-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-one | 95716-68-0 | / | / |
| (3R-trans)-[2-[3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]cyclohexylidene]ethyl]diphenyl-phosphine Oxide | 139356-39-1 | / | / |
| (1R,3aR,7aR)-1-((2R,5S,E)-6-(MethoxyMethoxy)-5,6-diMethylhept-3-en-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-one | 100858-26-2 | / | / |
| (((1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-(MethoxyMethoxy)-5,6-diMethylhept-3-en-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)cyclohexane-1,3-diyl)bis(oxy))bis(tert-butyldiMethylsilane) | 1435939-17-5 | / | / |
| (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-(MethoxyMethoxy)-5,6-diMethylhept-3-en-2-yl)-7a-Methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol | 1023889-38-4 | / | / |
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →